Hoth Therapeutics announced the granting of a U.S. patent for its pioneering Alzheimer’s treatment, HT-ALZ. This patent secures the company’s intellectual property rights to its novel therapeutic approach, as Hoth accelerates preparations for clinical trials.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HOTH:
- Hoth Therapeutics announces ‘encouraging’ results from trial of HT-ALZ
- Hoth announces expansion of clinical sites for HT-001 Phase 2a trial
- Hoth Therapeutics announces positive data from skin toxicities with HT-001
- Hoth Therapeutics assumed with a Buy at EF Hutton
- Hoth Therapeutics and Aronnax sign master services agreement for HT-KIT